よむ、つかう、まなぶ。
06【参考資料１】Interim statement on the composition of current COVID19 vaccines World Health Organization 17 June 2022 (6 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_26922.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会（第33回 7／22）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
1
data indicate that the inclusion of Omicron, as the most antigenically distinct
2
SARS-CoV-2 VOC, in an updated vaccine composition may be beneficial.
3
Available data also indicate that this would be best administered as a booster dose
4
to those who have already received a COVID-19 vaccination primary series, if
5
such vaccines were to be made available.
6
7
The TAG-CO-VAC acknowledges that this position is based on limited data from
8
animal models, inference from Omicron infection in primed and unprimed
9
individuals, and preliminary clinical data in humans vaccinated with an Omicron
10
vaccine candidate. The TAG-CO-VAC therefore recognizes that considerable
11
uncertainties remain. Firstly, uncertainty in the trajectory of SARS-CoV-2
12
evolution is such that there is a risk that this update may not align with variants
13
that emerge in the future. However, a modified vaccine composition that includes
14
Omicron will likely broaden the antibody response in primed individuals.
15
Secondly, there are assumptions as to the potential performance of variant-
16
specific vaccines, including Omicron-containing vaccines. It is assumed that the
17
safety, reactogenicity and immunogenicity of the updated vaccine composition
18
will be comparable to those of the currently licensed vaccines based on the index
19
virus. The TAG-CO-VAC therefore strongly encourages the generation of clinical
20
data on immune responses in humans to a primary series and/or booster dose of
21
Omicron-specific vaccines, across different vaccine platforms. These additional
22
data may then be considered by TAG-CO-VAC and will allow the Strategic
23
Advisory Group of Experts (SAGE) on Immunization and its COVID-19 Vaccines
24
Working Group to issue policy recommendations on the use and timing of
25
Omicron-specific vaccines.
26
27
The statement reflects the current vaccine performance and landscape of licensed
28
COVID-19 vaccines as of June 2022. The statement will therefore be updated as
29
further data become available.
30
31
_________________________________________
32
1. WHO. COVID-19 Weekly Epidemiological Update. 8 June 2022. Available
6
data indicate that the inclusion of Omicron, as the most antigenically distinct
2
SARS-CoV-2 VOC, in an updated vaccine composition may be beneficial.
3
Available data also indicate that this would be best administered as a booster dose
4
to those who have already received a COVID-19 vaccination primary series, if
5
such vaccines were to be made available.
6
7
The TAG-CO-VAC acknowledges that this position is based on limited data from
8
animal models, inference from Omicron infection in primed and unprimed
9
individuals, and preliminary clinical data in humans vaccinated with an Omicron
10
vaccine candidate. The TAG-CO-VAC therefore recognizes that considerable
11
uncertainties remain. Firstly, uncertainty in the trajectory of SARS-CoV-2
12
evolution is such that there is a risk that this update may not align with variants
13
that emerge in the future. However, a modified vaccine composition that includes
14
Omicron will likely broaden the antibody response in primed individuals.
15
Secondly, there are assumptions as to the potential performance of variant-
16
specific vaccines, including Omicron-containing vaccines. It is assumed that the
17
safety, reactogenicity and immunogenicity of the updated vaccine composition
18
will be comparable to those of the currently licensed vaccines based on the index
19
virus. The TAG-CO-VAC therefore strongly encourages the generation of clinical
20
data on immune responses in humans to a primary series and/or booster dose of
21
Omicron-specific vaccines, across different vaccine platforms. These additional
22
data may then be considered by TAG-CO-VAC and will allow the Strategic
23
Advisory Group of Experts (SAGE) on Immunization and its COVID-19 Vaccines
24
Working Group to issue policy recommendations on the use and timing of
25
Omicron-specific vaccines.
26
27
The statement reflects the current vaccine performance and landscape of licensed
28
COVID-19 vaccines as of June 2022. The statement will therefore be updated as
29
further data become available.
30
31
_________________________________________
32
1. WHO. COVID-19 Weekly Epidemiological Update. 8 June 2022. Available
6